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Strategies for improving patient behaviour and 
enhancing drug adherence exist but are often complex, 
requiring much one-to-one patient counselling, 
and they are often implemented too late, once poor 
habits have already been established. More value may 
therefore lie in thorough preparation of patients before 
commencing ART, rather than adherence interventions 
once patients are already on treatment. This is not only 
because consistent and efficacious drug therapy is life 
saving, but also because drug-resistant strains of HIV 
emerge in the presence of sub-therapeutic dosing due 
to sub-optimal adherence.2,3 The concept of ‘prevention 
is better than cure’ may therefore be applicable to the 
problem of non-adherence among patients on ART 
even more than in the management of chronic non-
infectious diseases in which drug resistance is not an 
issue of concern. 
We therefore undertook an analysis of results from the 
adherence monitoring in our HIV care and treatment 
programme to evaluate whether a change in the focus 
of conventional HIV treatment strategies would be 
effective in preventing non-adherence.
BACKGROUND INFORMATION ON THE HIV 
CARE AND TREATMENT PROGRAMME
Our programme, launched in 2003, is situated in Cato 
Manor, a ward of the eThekwini (Durban) Metro in 
KwaZulu-Natal, South Africa, which encompasses 
both low-cost housing and informal settlements and is 
notably an area of low income, with many households 
and families having no formal income generation. 
At the end of November 2008 we had 1 238 patients 
enrolled in HIV care, with 499 of them on ART (436 
adults and 63 children). The programme provides a 
patient-centred, rights-based, holistic approach to 
improving and maintaining the wellbeing of HIV-
positive mothers, any of their infected family members, 
and uninfected infants less than 1 year of age. Mothers 
are generally the primary caregivers in a Cato Manor 
household, so improvement and maintenance of their 
health, despite HIV infection, benefits the entire 
family, as they remain productive and fully functional 
as caregivers and/or breadwinners. The programme 
views HIV as a communicable but manageable chronic 
disease that affects the whole family unit. With a view 
to keeping family units strong, HIV-positive household 
members of existing programme participants are 
eligible for enrolment into HIV care and treatment. 
While the approach is to maintain good health 
before ART is indicated, once eligibility for ART is 
established patients are prepared, both medically 
and psychologically, for commencement of treatment 
according to World Health Organization (WHO) 
guidelines for the treatment of HIV infection. Medical 
preparation involves patient examination, evaluation 
of patient history, exclusion of current tuberculosis 
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(TB) infection, a full blood count, and kidney and liver 
function tests. Psychological readiness is assessed by 
trained HIV counsellors, who conduct drug readiness 
training before commencement of treatment. Drug 
readiness training is run over 3 weeks in small-group 
sessions and includes modules on positive living with HIV 
infection, preparation for appropriate administration of 
medicine and adherence to treatment regimens.
METHODS
MONITORING ADHERENCE
Adherence to treatment in adults receiving ART was 
monitored by pill count at scheduled clinic visits, and 
expressed as the percentage of the prescribed doses 
that had actually been taken since the previous visit. 
Data collected over a 1-year period (December 2007 
- November 2008) were analysed monthly, as well as 
retrospectively at the end of the observation period. 
At each visit patients were questioned as to whether 
they were having problems with adherence. Problems 
with adherence that were identified for specific 
patients during the course of the year were dealt with 
at the time by implementing one-to-one adherence 
counselling, education regarding medication, and the 
use of any other appropriate aids for helping patients 
to adhere to treatment.
RESULTS
GENERAL PATIENT DETAILS
At the end of the observation period (end November 
2008) there were 499 patients on ART (436 adults 
and 63 children). Of the adult group, 77 (17.7%) were 
male and 359 (82.3%) were female, and the mean 
age was 31.1 years (range 16 - 62 years). Patients had 
been on treatment in this programme for a mean of 
21.2 months (range 1 - 69 months). Twenty-one of the 
adults on ART were transferred into the programme 
already on treatment, and had a mean CD4 cell count 
of 406.3 cells/µl on entry to the programme. The 415 
treatment-naïve adults who were initiated on ART in 
our programme had a mean CD4 count of 141.5 cells/µl 
at initiation (range 0 - 675 cells/µl). 
While paediatric adherence monitoring was done 
at each visit, only results for the adult cohort were 
included in this analysis, as the number of children in 
the programme was comparatively small.
ADHERENCE TO TREATMENT
Analysis of pill count data showed that the mean 
adherence for every month throughout the year was 
above 94% and the mean adherence for the patient 
cohort over the entire observational period was 96.4% 
(standard deviation (SD) 6.7%), with 90% of patients 
achieving adherence of 90% or more and 78.5% 
achieving adherence of 95% or more. 
TREATMENT FAILURES AND MORTALITY
During this study (since 2003) 593 patients have been 
started on ART and there have been 6 treatment failures 
(1%), necessitating switching of patients to second-line 
regimens. Thirty-nine patients on ART have died while 
enrolled in the programme. Two deaths were due to 
injuries unrelated to ART and were therefore excluded 
from the deaths for the purposes of this analysis. Thirty-
seven deaths were due to opportunistic infections 
or other HIV-related diseases. None of the patients 
who died had suffered a known virological treatment 
failure before death and any changes to the regimen 
were of single drugs, due to pregnancy, drug toxicity 
or contraindications. More than half of the deaths 
occurred within the first 3 months of starting treatment 
(51%) and 73% within the first year, suggesting that 
a prominent factor contributing to death was late 
presentation at the clinic with advanced disease. 
EFFECTS OF ADHERENCE INTERVENTIONS AND MONITORING
Mean adherence values for the patient cohort increased 
throughout the observation period, with the lowest 
mean adherence (94.2%) reported in the 2nd month of 
adherence data collection, and the highest (97.4%) in the 
11th month. Additionally, the percentage of patients on 
ART who returned their unused medicine at clinic visits 
increased each month during the observation period, 
as patients became more aware of the importance of 
returning medicine at each visit. 
DISCUSSION
It is considered that a 95% adherence rate is required for 
sustained viral suppression in patients taking protease 
inhibitor (PI)-based regimens.4,5 The mean adherence 
reported here indicates that medication-taking behaviour 
for currently used antiretroviral drug regimens was 
acceptable. 
Our programme compares favourably with other studies 
that report mean adherence measured by medicine 
returns. A recent South African study in children reported 
79% of patients achieving adherence of 90% or more, 
measured by pill count,6 and data from a Botswana study 
in adults suggested this figure to be 74.4%,7 compared 
with 90% for patients in this programme. A 2003 South 
African study of HIV-positive adults reported that 63% 
of patients were 90% adherent or better, while the 
mean adherence for the patient cohort was 87.2%.8 
Considering the percentage of patients achieving 95% 
adherence or more, a large public sector antiretroviral 
treatment programme in Zambia reported 62.9% of 
patients with such adherence,9 more than 15% lower 
than the 78.5% of patients in our programme cohort. 
Two studies on HIV-positive adults in Kenya and Uganda 
reported similar adherence rates to those achieved in 
our programme, with 86.1% of patients in standard 
care achieving 95% adherence or more in the Kenyan 
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cohort10 and 87 - 94% (measured at different time 
points) achieving 95% adherence in the Uganda study.11 
Both these studies used medicine returns as well as self-
report methods of monitoring adherence.
The favourable adherence values measured over the 
observation period are evidenced by the low number 
of treatment failures of first-line ART regimens, and 
therefore only very few patients being switched to 
second-line treatment strategies (6 out of 593 patients). 
Adherence has been shown to have a direct impact on 
virological suppression4,7 and therefore on treatment 
success, and this is reflected in the positive patient 
outcomes seen in this programme. 
We observed an increase in mean adherence values for 
the patient cohort throughout the observation period. 
This improvement in mean adherence correlated with 
patients’ compliance with instructions regarding clinic 
visits and tablet returns. The mere practice of requesting 
that unused tablets be returned, and the consistent 
questioning by pharmacy staff concerning such unused 
tablets if they are not returned, raised adherence as a 
point of discussion with patients, resulting in improved 
patient interaction and better understanding regarding 
the importance of adherence. The pharmacy staff were 
given opportunities to discuss specific issues affecting 
adherence that patients reported when questioned 
regarding their unused medicine. During the collection 
of data for adherence measurement, other social and 
psychological issues surrounding the issue of adherence 
were identified. 
Our data showed that adherence behaviour of patients 
who returned unused medicine 50% of the time or more 
(i.e. 6 out of 12 months or more) was better than for 
those patients who only returned medication at less 
than 6 visits. Although the difference between the 
mean adherence for these two groups of patients is not 
statistically significant, the data may provide a useful 
tool for highlighting potential adherence problems, as 
well as a possible area of further research. Pharmacy 
refill adherence (measured as the percentage of expected 
pharmacy visits filled) has been shown to predict viral 
load suppression.12 
The extended time patients spend in the programme 
before starting lifelong treatment provides an 
opportunity for them to observe other patients who are 
starting treatment, and those who are thriving on ART, 
which reinforces the trust that is built up over several 
clinic visits and repeated interactions with programme 
staff. While still physically well, patients have time 
to work with counsellors towards accepting their HIV 
status and adapting their lifestyle to accommodate 
necessary routines, tasks and habits that will enhance 
their health, including disclosing their HIV status to 
family and/or household members. It is during this time 
that they become practically and emotionally prepared 
for starting treatment over the long term. Time to accept 
their HIV status is important for achieving preparedness 
for starting ART, and for maintaining good adherence 
over the long term.
This approach to treatment would be applicable to 
large-scale implementation in ARV roll-out programmes 
in resource-poor settings because the staff required 
to implement the preparative interventions in this 
programme are at the lay counsellor level. Expansion of 
the lay counsellor quota of a multidisciplinary team will 
add less of a financial burden on programme resources 
than would an increase in clinical staff. Additionally, the 
employment and training of such lay people provides 
employment and empowerment to people who live in the 
community that the programme serves. Employing local 
residents as lay counsellors enhances knowledge of the 
community, as well as access into the community and 
surrounding area, which helps in dealing with difficult 
patient and family situations through home visits and 
identification of patients who would otherwise be 
considered lost to follow-up.
On the basis of our results we conclude that preventing 
non-adherence is a better treatment approach than 
strategies in which the primary focus is on identifying and 
rectifying non-adherence once it has been established. 
We therefore recommend that HIV care and treatment 
facilities include such preparative approaches for 
promoting adherence into their treatment programmes.
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